The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Current Trends in The Use of Liposomes for Tumor Targeting
Open accessAbstract
The use of liposomes for drug delivery began early in the history of pharmaceutical nanocarriers. These nanosized, lipid bilayered vesicles have become popular as drug delivery systems owing to their efficiency, biocompatibility, nonimmunogenicity, enhanced solubility of chemotherapeutic agents and their ability to encapsulate a wide array of drugs. Passive and ligand-mediated active targeting promote tumor specificity with diminished adverse off-target effects. The current field of liposomes focuses on both clinical and diagnostic applications. Recent efforts have concentrated on the development of multifunctional liposomes that target cells and cellular organelles with a single delivery system. This review discusses the recent advances in liposome research in tumor targeting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Self-citationDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Maeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Self-citationNew-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
TORCHILIN, V (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.009 · Cited by 1,273
Self-citationLow, P. S., Henne, W. A., & Doorneweerd, D. D. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000815 · Cited by 1,173
Mesoporous Silica Nanoparticle Nanocarriers: Biofunctionality and Biocompatibility
Tarn, D., Ashley, C. E., Xue, M., Carnes, E. C., Zink, J. I., & Brinker, C. J. (2013) · Accounts of Chemical Research · doi:10.1021/ar3000986 · Cited by 949
Targeting nanoparticles to cancer
Wang, M., & Thanou, M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.005 · Cited by 931
Macromolecular therapeutics in cancer treatment: The EPR effect and beyond
Maeda, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.038 · Cited by 814
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. (2008) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 791
Targeted pharmaceutical nanocarriers for cancer therapy and imaging
Torchilin, V. P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902015 · Cited by 762
Self-citationAl-Jamal, W. T., & Kostarelos, K. (2011) · Accounts of Chemical Research · doi:10.1021/ar200105p · Cited by 696
Torchilin, V. P. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00166-4 · Cited by 680
Self-citationBatist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
Torchilin, V. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.026 · Cited by 583
Self-citationPassive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Self-citationZhu, L., Kate, P., & Torchilin, V. P. (2012) · ACS Nano · doi:10.1021/nn300524f · Cited by 489
Self-citationSilverman, J. A., & Deitcher, S. R. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2042-4 · Cited by 474
Liposome-based drug delivery in breast cancer treatment
Park, J. W. (2002) · Breast Cancer Research · doi:10.1186/bcr432 · Cited by 469
Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals
Ying, X., Wen, H., Lu, W.-L., Du, J., Guo, J., Tian, W., Men, Y., Zhang, Y., Li, R.-J., Yang, T.-Y., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.020 · Cited by 447
Multi-functional nanocarriers to overcome tumor drug resistance
Jabr-Milane, L. S., van Vlerken, L. E., Yadav, S., & Amiji, M. M. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.04.003 · Cited by 407
Lysosomal involvement in cell death and cancer
Kirkegaard, T., & Jäättelä, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.09.008 · Cited by 395
Mamot, C., Drummond, D. C., Noble, C. O., Kallab, V., Guo, Z., Hong, K., Kirpotin, D. B., & Park, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1093 · Cited by 382
Challenges in Development of Targeted Liposomal Therapeutics
Sawant, R. R., & Torchilin, V. P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9330-0 · Cited by 379
Self-citationReversible Cell‐Specific Drug Delivery with Aptamer‐Functionalized Liposomes
Cao, Z., Tong, R., Mishra, A., Xu, W., Wong, G. C. L., Cheng, J., & Lu, Y. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901452 · Cited by 372
Grüll, H., & Langereis, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.041 · Cited by 360
Gubernator, J. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.566552 · Cited by 325
Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery
MAE, M., & LANGEL, U. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.04.004 · Cited by 317
Human transferrin: cDNA characterization and chromosomal localization.
Yang, F., Lum, J. B., McGill, J. R., Moore, C. M., Naylor, S. L., van Bragt, P. H., Baldwin, W. D., & Bowman, B. H. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.9.2752 · Cited by 314
Mitochondrial gateways to cancer
Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Rigoni, A., Vacchelli, E., Michaud, M., Zischka, H., Castedo, M., & Kroemer, G. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.08.002 · Cited by 300
Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy
Gindy, M. E., & Prud'homme, R. K. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902932908 · Cited by 298
Koren, E., Apte, A., Jani, A., & Torchilin, V. P. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.002 · Cited by 293
Self-citationBiswas, S., Dodwadkar, N. S., Deshpande, P. P., & Torchilin, V. P. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.009 · Cited by 279
Self-citationNewman, M. S., Colbern, G. T., Working, P. K., Engbers, C., & Amantea, M. A. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050855 · Cited by 275
Targeted delivery of doxorubicin using stealth liposomes modified with transferrin
Li, X., Ding, L., Xu, Y., Wang, Y., & Ping, Q. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.01.023 · Cited by 274
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
Nanomedicine in cancer therapy: Innovative trends and prospects
Blanco, E., Hsiao, A., Mann, A. P., Landry, M. G., Meric‐Bernstam, F., & Ferrari, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01941.x · Cited by 265
Stimulus-responsive nanopreparations for tumor targeting
Zhu, L., & Torchilin, V. P. (2013) · Integrative Biology · doi:10.1039/c2ib20135f · Cited by 258
Self-citationPotential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer
Bolhassani, A. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.07.006 · Cited by 257
Liposomes as ‘smart’ pharmaceutical nanocarriers
Sawant, R. R., & Torchilin, V. P. (2010) · Soft Matter · doi:10.1039/b923535n · Cited by 243
Self-citationBoddapati, S. V., D’Souza, G. G. M., Erdogan, S., Torchilin, V. P., & Weissig, V. (2008) · Nano Letters · doi:10.1021/nl801908y · Cited by 234
Self-citationRecent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting
Perche, F., & Torchilin, V. P. (2013) · Journal of Drug Delivery · doi:10.1155/2013/705265 · Cited by 230
Self-citationA Review on Composite Liposomal Technologies for Specialized Drug Delivery
Mufamadi, M. S., Pillay, V., Choonara, Y. E., Du Toit, L. C., Modi, G., Naidoo, D., & Ndesendo, V. M. K. (2011) · Journal of Drug Delivery · doi:10.1155/2011/939851 · Cited by 229
Hyperthermia-induced drug targeting
May, J. P., & Li, S.-D. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.758631 · Cited by 228
Expert opinion: Responsive polymer nanoparticles in cancer therapy
Liechty, W. B., & Peppas, N. A. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.08.004 · Cited by 226
Lipoplatin Formulation Review Article
Stathopoulos, G. P., & Boulikas, T. (2012) · Journal of Drug Delivery · doi:10.1155/2012/581363 · Cited by 224
Efficient Oncogene Silencing and Metastasis Inhibition via Systemic Delivery of siRNA
Li, S.-D., Chono, S., & Huang, L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.51 · Cited by 198
Tumor targeting using liposomal antineoplastic drugs
Huwyler, J. (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s1253 · Cited by 182
Drug Targeting Strategies in Cancer Treatment: An Overview
L. Arias, J. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711793564024 · Cited by 176
Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide
Garg, A., Tisdale, A. W., Haidari, E. S., & Kokkoli, E. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.09.016 · Cited by 174
A liposome-based nanostructure for aptamer directed delivery
Kang, H., O’Donoghue, M. B., Liu, H., & Tan, W. (2010) · Chem. Commun. · doi:10.1039/b916911c · Cited by 169
Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes
Hatakeyama, H., Akita, H., Ishida, E., Hashimoto, K., Kobayashi, H., Aoki, T., Yasuda, J., Obata, K., Kikuchi, H., Ishida, T., et al. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.04.037 · Cited by 165
Localised drug release using MRI-controlled focused ultrasound hyperthermia
Staruch, R., Chopra, R., & Hynynen, K. (2011) · International Journal of Hyperthermia · doi:10.3109/02656736.2010.518198 · Cited by 159
VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo
Gosk, S., Moos, T., Gottstein, C., & Bendas, G. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.12.021 · Cited by 158
Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics
Mok, H., & Zhang, M. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.747507 · Cited by 156
Cauda, V., Engelke, H., Sauer, A., Arcizet, D., Rädler, J., & Bein, T. (2010) · Nano Letters · doi:10.1021/nl100991w · Cited by 155
Yarmolenko, P., Zhao, Y., Landon, C. D., Spasojević, I., Yuan, F., Needham, D., Viglianti, B. L., & Dewhirst, M. W. (2010) · International Journal of Hyperthermia · doi:10.3109/02656731003789284 · Cited by 154
Designing of ‘intelligent’ liposomes for efficient delivery of drugs
Voinea, M., & Simionescu, M. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00450.x · Cited by 152
Rodriguez, M. A., Pytlík, R., Kozák, T., Chhanabhai, M., Gascoyne, R. D., Lu, B., Deitcher, S. R., & Winter, J. N. (2009) · Cancer · doi:10.1002/cncr.24359 · Cited by 145
Sarris, A. H., Hagemeister, F. B., Romaguera, J. E., Rodríguez, M., McLaughlin, P. J., Tsimberidou, A. M., Medeiros, L. J., Samuels, B. I., Pate, O., Oholendt, M. S., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008348010437 · Cited by 143
Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes
Qi, X., Zhao, Z., & zhuang, Z. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s25399 · Cited by 137
Yamada, Y., Furukawa, R., Yasuzaki, Y., & Harashima, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.99 · Cited by 136
Current Trends in Liposome Research
ElBayoumi, T. A., & Torchilin, V. P. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-360-2_1 · Cited by 136
Self-citationLiposomal daunorubicin as treatment for Kaposi’s sarcoma
Dittmer, D. P., & Petre, C. E. (2007) · PubMed Central · doi:10.17615/wyf0-9n94 · Cited by 130
Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes
Xiang, G., Wu, J. H., Lu, Y., Liu, Z., & Lee, R. J. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.12.030 · Cited by 126
Targeting of Nanoparticles: Folate Receptor
Kularatne, S. A., & Low, P. S. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-609-2_17 · Cited by 120
Sasaki, K., Kogure, K., Chaki, S., Nakamura, Y., Moriguchi, R., Hamada, H., Danev, R., Nagayama, K., Futaki, S., & Harashima, H. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2012-1 · Cited by 115
Targeting of nanoparticles in cancer
Talekar, M., Kendall, J. D., Denny, W. A., & Garg, S. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834a4554 · Cited by 115
Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors
Chang, D.-K., Chiu, C., Kuo, S.-Y., Lin, W.-C., Lo, A., Wang, Y., Li, P., & Wu, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900280200 · Cited by 109
Poon, R. T. P., & Borys, N. (2011) · Future Oncology · doi:10.2217/fon.11.73 · Cited by 108
Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer.
Seetharamu, N., Kim, E., Höchster, H. S., Martin, F., & Muggia, F. M. (2010) · PubMed · Cited by 107
Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
Stathopoulos, G. P., Antoniou, D., Dimitroulis, J., Stathopoulos, J., Marosis, K., & Michalopoulou, P. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1572-5 · Cited by 102
Semple, S. C., Leone, R., Wang, J., Leng, E. C., Klimuk, S. K., Eisenhardt, M. L., Yuan, Z.-N., Edwards, K., Maurer, N., Hope, M. J., et al. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20332 · Cited by 101
Fasol, U., Frost, A., Büchert, M., Arends, J., Fiedler, U., Scharr, D., Scheuenpflug, J., & Mross, K. B. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr300 · Cited by 101
WICKI, A. N., Rochlitz, C. F., Orleth, A., Ritschard, R., Albrecht, I., Herrmann, R., Christofori, G., & Mamot, C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1102 · Cited by 101
Chen, Z., Deng, Zhao, Z., & Tao, T. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33541 · Cited by 99
Uptake and trafficking of liposomes to the endoplasmic reticulum
Pollock, S., Antrobus, R., Newton, L., Kampa, B., Rossa, J., Latham, S., Nichita, N. B., Dwek, R. A., & Zitzmann, N. (2010) · The FASEB Journal · doi:10.1096/fj.09-145755 · Cited by 99
Shmeeda, H., Tzemach, D., Mak, L., & Gabizón, A. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.02.002 · Cited by 98
Shmeeda, H., Amitay, Y., Gorin, J., Tzemach, D., Mak, L., Ogorka, J., Kumar, S., Zhang, J. A., & Gabizón, A. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.028 · Cited by 96
Paszko, E., & Senge, M. O. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803833362 · Cited by 96
A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors
Zhang, Q., Huang, X., & Gao, L. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.10.001 · Cited by 93
Koshkaryev, A., Piroyan, A., & Torchilin, V. P. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.1.18871 · Cited by 92
Self-citationTreatment of Acute Lymphoblastic Leukaemia
Apostolidou, E., Swords, R. T., Alvarado, Y., & Giles, F. J. (2007) · Drugs · doi:10.2165/00003495-200767150-00004 · Cited by 91
Thioaptamer Conjugated Liposomes for Tumor Vasculature Targeting
Mann, A. P., Bhavane, R. C., Somasunderam, A., Montalvo-Ortiz, B. L., Ghaghada, K. B., Volk, D. E., Nieves-Alicea, R., Suh, K. S., Mauro Ferrari, B., Annapragada, A., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.261 · Cited by 91
Pal, A., Khan, S., Wang, Y.-F., Kamath, N., Sarkar, A., Ahmad, A., Sheikh, S., Ali, S., Carbonaro, D., Zhang, A., et al. (2005) · PubMed · Cited by 91
Chou, H., Wang, K., Chen, C., Wei, L., Lai, C., Hsieh, C., Yang, Y., Twu, N.-F., Chang, T., & Yen, M. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.10.027 · Cited by 90
Tf-lipoplexes for neuronal siRNA delivery: A promising system to mediate gene silencing in the CNS
Cardoso, A. L., Simões, S., de Almeida, L. P., Plesnila, N., de Lima, M. C. P., Wagner, E., & Culmsee, C. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.08.014 · Cited by 86
Biswas, S., Dodwadkar, N. S., Sawant, R. R., Koshkaryev, A., & Torchilin, V. P. (2011) · Journal of drug targeting · doi:10.3109/1061186x.2010.536983 · Cited by 86
Self-citationUse of nanoscale delivery systems to maintain synergistic drug ratiosin vivo
Dicko, A., Mayer, L. D., & Tardi, P. G. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.538678 · Cited by 86
Sharma, G., Modgil, A., Sun, C., & Singh, J. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23152 · Cited by 84
Multicomponent folate-targeted magnetoliposomes: design, characterization, and cellular uptake
Bothun, G. D., Lelis, A., Chen, Y., Scully, K., Anderson, L. E., & Stoner, M. A. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.02.007 · Cited by 84
Malhi, S. S., Budhiraja, A., Arora, S., Chaudhari, K. R., Nepali, K., Kumar, R., Sohi, H., & Murthy, R. S. R. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.030 · Cited by 82
Biswas, S., Dodwadkar, N. S., Deshpande, P. P., Parab, S., & Torchilin, V. P. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.12.021 · Cited by 81
Self-citationLiposomes and Liposome-like Vesicles for Drug and DNA Delivery to Mitochondria
Weissig, V., Boddapati, S. V., Cheng, S.-M., & D’Souza, G. G. M. (2006) · Journal of Liposome Research · doi:10.1080/08982100600851169 · Cited by 81
Release of Liposomal Contents by Cell-Secreted Matrix Metalloproteinase-9
Banerjee, J., Hanson, A. J., Gadam, B., Elegbede, A. I., Tobwala, S., Ganguly, B., Wagh, A. V., Muhonen, W. W., Law, B., Shabb, J. B., et al. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9000646 · Cited by 79
Nanoparticle delivery of a peptide targeting EGFR signaling
Kim, S. K., & Huang, L. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.014 · Cited by 75
Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes
Gao, J., Zhong, W. H., He, J., Li, H., Zhang, H., Zhou, G., Li, B., Lü, Y., Zou, H. L., Kou, G., et al. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.03.018 · Cited by 71
Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer
Booser, D. J., Esteva, F. J., Rivera, E., Valero, V., Esparza-Guerra, L., Priebe, W., & Hortobágyi, G. N. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0464-0 · Cited by 67
Goldenbogen, B., Brodersen, N., Gramatica, A., Loew, M., Liebscher, J., Herrmann, A., Egger, H., Budde, B., & Arbuzova, A. (2011) · Langmuir · doi:10.1021/la201160y · Cited by 64
Roggers, R. A., Lin, V. S. ‐., & Trewyn, B. G. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200613y · Cited by 61
Chiu, G. N. C., Edwards, L., Kapanen, A. I., Malinen, M. M., Dragowska, W. H., Warburton, C., Chikh, G., Fang, K. Y. Y., Tan, S., Sy, J., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0159 · Cited by 59
Environment-Responsive Multifunctional Liposomes
Kale, A. A., & Torchilin, V. P. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-360-2_15 · Cited by 56
Self-citationFunctional coating of liposomes using a folate–polymer conjugate to target folate receptors
Maitani, Y., Kaneko, & †↑, W. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s32853 · Cited by 56
Pre-Targeting and Direct Immunotargeting of Liposomal Drug Carriers to Ovarian Carcinoma
Lehtinen, J., Raki, M., Bergström, K., Uutela, P., Lehtinen, K., Hiltunen, A., Pikkarainen, J. T., Liang, H., Pitkänen, S., Määttä, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041410 · Cited by 56
Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition
Koshkaryev, A., Piroyan, A., & Torchilin, V. P. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.06.008 · Cited by 54
Self-citationLipoplatin Treatment in Lung and Breast Cancer
Fantini, M., Gianni, L., Santelmo, C., Drudi, F., Castellani, C., Affatato, A. A., Nicolini, M., & Ravaioli, A. (2010) · Chemotherapy Research and Practice · doi:10.1155/2011/125192 · Cited by 53
Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins
Yoon, D. J., Chu, D. S. H., Ng, C., et al. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.10.006 · Cited by 52
Ayen, W. Y., & Kumar, N. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0783-8 · Cited by 51
Chiu, G. N. C., Chaudhury, Das, & Bunte (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s26172 · Cited by 45
Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B
Koshkaryev, A., Thekkedath, R., Pagano, C., Meerovich, I. G., & Torchilin, V. P. (2011) · Journal of drug targeting · doi:10.3109/1061186x.2010.550921 · Cited by 43
Self-citationKang, D. I., Lee, S., Lee, J. T., et al. (2011) · Journal of Microencapsulation · doi:10.3109/02652048.2011.552989 · Cited by 39
El-Hamed, F., Dave, N., & Liu, J. (2011) · Nanotechnology · doi:10.1088/0957-4484/22/49/494011 · Cited by 38
Imaging Characteristics of Zinc Sulfide Shell, Cadmium Telluride Core Quantum Dots
Daneshvar, H., Nelms, J., Muhammad, O., Jackson, H., Tkach, J. A., Davros, W. J., Peterson, T. E., Vogelbaum, M. A., Bruchez, M. P., & Toms, S. A. (2008) · Nanomedicine · doi:10.2217/17435889.3.1.21 · Cited by 37
Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes
Katanasaka, Y., Ida, T., Asai, T., Maeda, N., & Oku, N. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.046 · Cited by 36
Ling, S. S. N., Yuen, K. H., Magosso, E., & Barker, S. A. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.04.0005 · Cited by 35
Effect of Transferrin As a Ligand of pH-Sensitive Fusogenic Liposome−Lipoplex Hybrid Complexes
Sakaguchi, N., Kojima, C., Harada, A., Koiwai, K., Emi, N., & Kono, K. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800126s · Cited by 29
Ultrasound mediated localized drug delivery.
Ibsen, S., Benchimol, M. J., Simberg, D., & Esener, S. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-007-2555-3_14 · Cited by 22
Sun, X., Zhong, Yuwan, Sanjunshi, Jianfenghan, & Zhi-RongZhang (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s19745 · Cited by 18
Penacho, N., Rosa, M., Lindman, B., Miguel, M. G., Simões, S., & de Lima, M. C. P. (2009) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2009.10.034 · Cited by 12
Djafarzadeh, R., Milani, V., Rieth, N., von Luettichau, I., Skrablin, P. S. A., Hofstetter, M., Noeßner, E., & Nelson, P. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0559-5 · Cited by 11
Wong, A. S. H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007391 · Cited by 5
Cited by
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Self-citationEffective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances
Narayan, R., Nayak, U. Y., Raichur, A. M., & Garg, S. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030118 · Cited by 942
Metadata
- Authors
- Deshpande, P. P., Biswas, S., & Torchilin, V. P.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2013-08-05
- Volume
- 8
- Issue
- 9
- Pages
- 1509-1528
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2096552337
- Cited by
- 657
- References
- 127
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.